GRASS VALLEY, Calif.--(BUSINESS WIRE)--June 20, 2002



Biozhem Cosmeceuticals Inc. (OTCBB:BZHM), a developer and marketer of advanced skin care products, today announced that it has received the commitment of Thane International Inc. (Thane), a global leader in direct response marketing, to accelerate the RevitaCel Campaign nationally and internationally.



The commitment follows a successful 30 day testing period of the infomercial starring Emmy(R) award-winning actress Lindsay Wagner.



Thane, having conducted successful tests of the Biozhem RevitaCel infomercial, intends to aggressively move forward with the RevitaCel campaign. As previously reported, Thane has contracted with Biozhem to finance and manage all aspects of Biozhem's RevitaCel System(TM) domestic direct response and international campaign, including media buying, marketing and inventory funding, operations and fulfillment management.



Under the terms of the agreement, Thane had a 30 day period to test the infomercial prior to financing further activities. Now that the test period has been successfully completed, Thane has made an additional economic commitment to Biozhem's RevitaCel project. Today's announcement assures Thane's continued involvement.



"We have completed our evaluation of the RevitaCel System and the infomercial, and have been very impressed with its performance," said Bill Hay, CEO of Thane International. "We are very excited by the prospects of marketing this unique product, and we look forward to accelerating the roll-out of the RevitaCel System to consumers around the nation and the world."



Biozhem, under the terms of the agreement, will retain ownership of the RevitaCel product line containing NouriCel(TM), while continuing to lead product development efforts and provide overall strategic direction. Thane will leverage its extensive media buying power and global distribution network to accelerate the worldwide rollout of the RevitaCel System through a wider array of direct response channels.



"We are gratified by Thane's continued confidence in the RevitaCel System," said James S. Chapin, Biozhem's CEO and chairman. "With more than a decade of experience in global marketing, specializing in direct response, Thane provides the expertise, financial resources, infrastructure and global reach that will allow us to reach new levels of success with RevitaCel and quickly maximize the revenue potential of the RevitaCel System," said Chapin. "We were quite confident that Thane's testing would validate the potential of our product. We have maintained that the global potential of our unique product, which duplicates how nature keeps skin young, will be greatly enhanced by Thane's expertise and resources."



The flagship product of the RevitaCel System, RevitaCel Replenishing Complex, contains NouriCel(TM), the first and only cosmetic ingredient derived from a patented process for growing human-based tissues for repair and transplantation.



NouriCel contains a unique cocktail of natural growth factors, antioxidants, matrix proteins and soluble collagens -- all compounds produced by healthy new skin, but which aging skin makes in smaller and smaller quantities. Biozhem exclusively licenses the marketing rights to NouriCel for skin care products in the global direct response market from BioNuvia Inc., a wholly owned subsidiary of Advanced Tissue Sciences.



Biozhem is exploring the use of NouriCel in additional skin care products and for other applications. In addition, Biozhem has the rights for NouriCel in the direct response market for nail and lip care.



"We are pleased that Thane and Biozhem are continuing to make progress in bringing the RevitaCel System to consumers looking for skin that appears younger and healthier," said Kerry Vail, vice president and general manager of BioNuvia. "We believe that Thane's resources and experience in the direct response market will help drive demand and maximize the sales potential of the RevitaCel System."



Statements about the company's future expectations and all other statements in this news release other than historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that is defined in the Private Litigation Reform Act of 1995. The company intends that such forward-looking statements be subject to the safe harbor created thereby. Since these statements involve risks and uncertainties and are subject to change at any time, the company's actual results could differ materially from expected results.